For a mild-moderate flare of distal ulcerative colitis, the recommended first-line treatment is rectal aminosalicylates. This is particularly effective if the inflammation is limited to the rectum. If rectal aminosalicylates are not effective, oral aminosalicylates may be used in combination with or instead of the topical treatment. However, if the patient has contraindications or intolerances to aminosalicylates, topical or oral steroids may be preferred. Intravenous steroids are typically reserved for severe flares of colitis with symptoms such as frequent bloody stools, systemic upset, anemia, or elevated inflammatory markers.

Ulcerative colitis can be managed through inducing and maintaining remission. The severity of the condition is classified as mild, moderate, or severe based on the number of stools and presence of systemic upset. Treatment for mild-to-moderate cases of proctitis involves using topical aminosalicylate, while proctosigmoiditis and left-sided ulcerative colitis may require a combination of oral and topical medications. Extensive disease may require a high-dose oral aminosalicylate and topical treatment. Severe colitis should be treated in a hospital with intravenous steroids or ciclosporin. Maintaining remission can involve using a low maintenance dose of an oral aminosalicylate or oral azathioprine/mercaptopurine. Methotrexate is not recommended, but probiotics may prevent relapse in mild to moderate cases.

Referral for Investigation of Colorectal Cancer with a 2-Week Wait

According to the National Institute for Health and Care Excellence (NICE) guidelines, patients aged 40 or over who present with unexplained weight loss and abdominal pain should be referred for investigation of colorectal cancer with a 2-week wait. Other criteria for a 2-week wait referral include patients with unexplained rectal bleeding, iron-deficiency anaemia, change in bowel habit, positive faecal occult blood tests, rectal or abdominal mass, unexplained anal mass or anal ulceration, and patients under 50 years with rectal bleeding and any of the following unexplained symptoms or findings: abdominal pain, change in bowel habit, weight loss or iron-deficiency anaemia.

Doing nothing and just following up with the patient, prescribing analgesia and following up in one month, referring the patient routinely, or taking urgent bloods and following up in two weeks would not be appropriate in the presence of red-flag symptoms and can create a serious delay in diagnosis and treatment. Therefore, referral for investigation of colorectal cancer with a 2-week wait is the recommended course of action. However, taking urgent bloods and following up the patient in two weeks can still be done while the patient is waiting for the referral appointment.

Understanding and Managing Irritable Bowel Syndrome (IBS)

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder that affects 10-20% of the population, with women being more likely to develop it than men. It is characterized by abdominal pain, bloating, and altered bowel habits without any specific organic pathology.

Diagnosis of IBS is based on the presence of symptoms such as abdominal pain or discomfort, bloating, and change in bowel habit for at least 6 months. Physical examination and further investigations are necessary to exclude other differential diagnoses.

Management of IBS primarily involves psychological support and dietary measures such as fiber supplementation, low FODMAP diets, increased water intake, and avoiding trigger foods. Pharmacological treatment is adjunctive and should be directed at symptoms. Anti-spasmodics, anti-diarrheals, and antidepressants may have a positive effect on symptoms.

It is important to note that symptoms not consistent with IBS, such as rectal bleeding, anorexia/weight loss, nocturnal symptoms, or fecal incontinence, should alert the clinician to the possibility of an organic pathology. Referral for psychological therapies should be considered for patients who do not respond to pharmacological treatments after 12 months and who develop a continuing symptom profile.

Both Crohn’s and UC have arthritis as their most common extra-intestinal feature.

Understanding Crohn’s Disease

Crohn’s disease is a type of inflammatory bowel disease that affects various parts of the digestive tract, from the mouth to the anus. Although the exact cause of Crohn’s disease is unknown, there is a strong genetic susceptibility. The disease is characterized by inflammation in all layers of the digestive tract, which can lead to complications such as strictures, fistulas, and adhesions. Symptoms of Crohn’s disease typically appear in late adolescence or early adulthood and may include non-specific symptoms such as weight loss and lethargy, diarrhea, abdominal pain, and perianal disease. Extra-intestinal features, such as arthritis, erythema nodosum, and osteoporosis, are also common in patients with Crohn’s disease.

To diagnose Crohn’s disease, doctors may look for raised inflammatory markers, increased faecal calprotectin, anemia, and low levels of vitamin B12 and vitamin D. It is important to note that Crohn’s disease shares some extra-intestinal features with ulcerative colitis, another type of inflammatory bowel disease. Arthritis is the most common extra-intestinal feature in both Crohn’s disease and ulcerative colitis, while primary sclerosing cholangitis is much more common in ulcerative colitis. Understanding the symptoms and features of Crohn’s disease can help with early diagnosis and management of the disease.

Understanding Crohn’s Disease

Crohn’s disease is a type of inflammatory bowel disease that affects various parts of the digestive tract, from the mouth to the anus. Although the exact cause of Crohn’s disease is unknown, there is a strong genetic susceptibility. The disease is characterized by inflammation in all layers of the digestive tract, which can lead to complications such as strictures, fistulas, and adhesions. Symptoms of Crohn’s disease typically appear in late adolescence or early adulthood and may include non-specific symptoms such as weight loss and lethargy, diarrhea, abdominal pain, and perianal disease. Extra-intestinal features, such as arthritis, erythema nodosum, and osteoporosis, are also common in patients with Crohn’s disease.

To diagnose Crohn’s disease, doctors may look for raised inflammatory markers, increased faecal calprotectin, anemia, and low levels of vitamin B12 and vitamin D. It is important to note that Crohn’s disease shares some extra-intestinal features with ulcerative colitis, another type of inflammatory bowel disease. Arthritis is the most common extra-intestinal feature in both Crohn’s disease and ulcerative colitis, while primary sclerosing cholangitis is much more common in ulcerative colitis. Understanding the symptoms and features of Crohn’s disease can help with early diagnosis and management of the disease.

Pseudopolyps observed during endoscopy are indicative of ulcerative colitis.

Crohn’s disease and ulcerative colitis are the two main types of inflammatory bowel disease with many similarities in symptoms and management options. However, there are key differences such as non-bloody diarrhea and upper gastrointestinal symptoms being more common in Crohn’s disease, while bloody diarrhea and abdominal pain in the left lower quadrant are more common in ulcerative colitis. Complications and pathology also differ between the two diseases.

For a patient experiencing a mild to moderate flare-up of ulcerative colitis that extends beyond the left-sided colon, it is recommended to supplement rectal aminosalicylates with oral aminosalicylates. This is because enemas have limited reach and may not effectively treat the disease outside of their range.

Ulcerative colitis can be managed through inducing and maintaining remission. The severity of the condition is classified as mild, moderate, or severe based on the number of stools and presence of systemic upset. Treatment for mild-to-moderate cases of proctitis involves using topical aminosalicylate, while proctosigmoiditis and left-sided ulcerative colitis may require a combination of oral and topical medications. Extensive disease may require a high-dose oral aminosalicylate and topical treatment. Severe colitis should be treated in a hospital with intravenous steroids or ciclosporin. Maintaining remission can involve using a low maintenance dose of an oral aminosalicylate or oral azathioprine/mercaptopurine. Methotrexate is not recommended, but probiotics may prevent relapse in mild to moderate cases.

There is insufficient evidence to support the use of PPIs in stopping bleeding, as in most cases, bleeding ceases without their administration. Administering IV proton pump inhibitors and fresh frozen plasma prior to endoscopy is incorrect, as PPIs should not be given and fresh frozen plasma should only be given to patients with specific blood clotting abnormalities.

Acute upper gastrointestinal bleeding is a common and significant medical issue that can be caused by various conditions, with oesophageal varices and peptic ulcer disease being the most common. The clinical features of this condition include haematemesis, melena, and a raised urea level due to the protein meal of the blood. The differential diagnosis for acute upper gastrointestinal bleeding includes oesophageal, gastric, and duodenal causes.

The management of acute upper gastrointestinal bleeding involves risk assessment using the Glasgow-Blatchford score, which helps clinicians decide whether patients can be managed as outpatients or not. Resuscitation is also necessary, including ABC, wide-bore intravenous access, and platelet transfusion if actively bleeding platelet count is less than 50 x 10*9/litre. Endoscopy should be offered immediately after resuscitation in patients with a severe bleed, and all patients should have endoscopy within 24 hours.

For non-variceal bleeding, proton pump inhibitors (PPIs) should not be given before endoscopy to patients with suspected non-variceal upper gastrointestinal bleeding. However, PPIs should be given to patients with non-variceal upper gastrointestinal bleeding and stigmata of recent haemorrhage shown at endoscopy. If further bleeding occurs, options include repeat endoscopy, interventional radiology, and surgery. For variceal bleeding, terlipressin and prophylactic antibiotics should be given to patients at presentation, and band ligation should be used for oesophageal varices and injections of N-butyl-2-cyanoacrylate for patients with gastric varices. Transjugular intrahepatic portosystemic shunts (TIPS) should be offered if bleeding from varices is not controlled with the above measures.

Ulcerative colitis can be managed through inducing and maintaining remission. The severity of the condition is classified as mild, moderate, or severe based on the number of stools and presence of systemic upset. Treatment for mild-to-moderate cases of proctitis involves using topical aminosalicylate, while proctosigmoiditis and left-sided ulcerative colitis may require a combination of oral and topical medications. Extensive disease may require a high-dose oral aminosalicylate and topical treatment. Severe colitis should be treated in a hospital with intravenous steroids or ciclosporin. Maintaining remission can involve using a low maintenance dose of an oral aminosalicylate or oral azathioprine/mercaptopurine. Methotrexate is not recommended, but probiotics may prevent relapse in mild to moderate cases.

The man in this scenario is experiencing Charcot’s triad, which includes right upper quadrant pain, fever, and jaundice. These symptoms suggest that he may have ascending cholangitis, which is caused by a bacterial infection in the biliary tree due to obstruction from biliary stasis (likely caused by his gallstones). Treatment involves resuscitation, IV antibiotics, and biliary drainage.

Understanding Ascending Cholangitis

Ascending cholangitis is a bacterial infection that affects the biliary tree, with E. coli being the most common culprit. This condition is often associated with gallstones, which can predispose individuals to the infection. Patients with ascending cholangitis may present with Charcot’s triad, which includes fever, right upper quadrant pain, and jaundice. However, this triad is only present in 20-50% of cases. Other common symptoms include hypotension and confusion. In severe cases, Reynolds’ pentad may be observed, which includes the additional symptoms of hypotension and confusion.

To diagnose ascending cholangitis, ultrasound is typically used as a first-line investigation to look for bile duct dilation and stones. Raised inflammatory markers may also be observed. Treatment involves intravenous antibiotics and endoscopic retrograde cholangiopancreatography (ERCP) after 24-48 hours to relieve any obstruction.

Overall, ascending cholangitis is a serious condition that requires prompt diagnosis and treatment. Understanding the symptoms and risk factors associated with this condition can help individuals seek medical attention early and improve their chances of a successful recovery.

If a person with Addison’s disease experiences vomiting, they should take IM hydrocortisone until the vomiting stops. This is especially important if the vomiting is caused by food poisoning from undercooked meat. IM hydrocortisone is a glucocorticoid steroid hormone that is used to manage Addison’s disease and prevent an Addisonian crisis. It is important to note that doubling the fludrocortisone dose or pausing hydrocortisone is not the correct approach in this situation. The patient requires extra hydrocortisone to prevent an Addisonian crisis, not extra fludrocortisone. While drinking plenty of fluids is generally good advice for someone who is vomiting, it is not sufficient for a person with Addison’s disease in this situation.

Addison’s disease is a condition that requires patients to undergo both glucocorticoid and mineralocorticoid replacement therapy. This treatment usually involves taking a combination of hydrocortisone and fludrocortisone. Hydrocortisone is typically given in 2 or 3 divided doses, with patients requiring 20-30 mg per day, mostly in the first half of the day. Patient education is crucial, and it is essential to emphasize the importance of not missing glucocorticoid doses. Additionally, patients should consider wearing MedicAlert bracelets and steroid cards, and they should be provided with hydrocortisone for injection with needles and syringes to treat an adrenal crisis.

During an intercurrent illness, it is crucial to manage the glucocorticoid dose properly. In simple terms, the glucocorticoid dose should be doubled, while the fludrocortisone dose should remain the same. The Addison’s Clinical Advisory Panel has produced guidelines that detail specific scenarios, and patients should refer to these guidelines for more information. It is essential to discuss how to adjust the glucocorticoid dose during an intercurrent illness with a healthcare professional. Proper management of Addison’s disease is crucial to ensure that patients can lead healthy and fulfilling lives.

For patients with non-alcoholic fatty liver disease who exhibit characteristics such as obesity and type 2 diabetes mellitus, it is recommended to conduct an enhanced liver fibrosis (ELF) test to aid in the diagnosis of liver fibrosis. According to NICE guidelines, if NAFLD is discovered incidentally, an ELF blood test should be conducted to evaluate for the presence of more advanced liver disease.

Non-Alcoholic Fatty Liver Disease: Causes, Features, and Management

Non-alcoholic fatty liver disease (NAFLD) is a prevalent liver disease in developed countries, primarily caused by obesity. It encompasses a range of conditions, from simple steatosis (fat accumulation in the liver) to steatohepatitis (fat with inflammation) and may progress to fibrosis and liver cirrhosis. Insulin resistance is believed to be the primary mechanism leading to steatosis, making NAFLD a hepatic manifestation of metabolic syndrome. Non-alcoholic steatohepatitis (NASH) is a type of liver damage similar to alcoholic hepatitis but occurs in the absence of alcohol abuse. It affects around 3-4% of the general population and may be responsible for some cases of cryptogenic cirrhosis.

NAFLD is usually asymptomatic, but hepatomegaly, increased echogenicity on ultrasound, and elevated ALT levels are common features. The enhanced liver fibrosis (ELF) blood test is recommended by NICE to check for advanced fibrosis in patients with incidental NAFLD. If the ELF blood test is not available, non-invasive tests such as the FIB4 score or NAFLD fibrosis score, in combination with a FibroScan, may be used to assess the severity of fibrosis. Patients with advanced fibrosis should be referred to a liver specialist for further evaluation, which may include a liver biopsy to stage the disease more accurately.

The mainstay of NAFLD treatment is lifestyle changes, particularly weight loss, and monitoring. Research is ongoing into the role of gastric banding and insulin-sensitizing drugs such as metformin and pioglitazone. While there is no evidence to support screening for NAFLD in adults, NICE guidelines recommend the management of incidental NAFLD findings.

The presence of fever, jaundice and right upper quadrant pain is known as Charcot’s cholangitis triad, which indicates an infection of the bile ducts. This patient is likely suffering from ascending cholangitis. Cholecystitis, which is inflammation of the gallbladder, can also cause right upper quadrant pain and may precede ascending cholangitis. While gallstones are a common cause of cholangitis, they can be asymptomatic and are not a diagnosis on their own. Pregnancy is not a likely cause of right upper quadrant pain. Gilbert’s syndrome typically causes mild jaundice only during times of stress and is usually asymptomatic.

Understanding Ascending Cholangitis

Ascending cholangitis is a bacterial infection that affects the biliary tree, with E. coli being the most common culprit. This condition is often associated with gallstones, which can predispose individuals to the infection. Patients with ascending cholangitis may present with Charcot’s triad, which includes fever, right upper quadrant pain, and jaundice. However, this triad is only present in 20-50% of cases. Other common symptoms include hypotension and confusion. In severe cases, Reynolds’ pentad may be observed, which includes the additional symptoms of hypotension and confusion.

To diagnose ascending cholangitis, ultrasound is typically used as a first-line investigation to look for bile duct dilation and stones. Raised inflammatory markers may also be observed. Treatment involves intravenous antibiotics and endoscopic retrograde cholangiopancreatography (ERCP) after 24-48 hours to relieve any obstruction.

Overall, ascending cholangitis is a serious condition that requires prompt diagnosis and treatment. Understanding the symptoms and risk factors associated with this condition can help individuals seek medical attention early and improve their chances of a successful recovery.

Differential Diagnosis for Abdominal Pain: Chronic Mesenteric Ischaemia, Chronic Pancreatitis, Diverticulitis, Gastric Cancer, and Acute Mesenteric Ischaemic Embolism

Abdominal pain is a common presenting symptom in clinical practice, and it can be caused by a variety of conditions. In this article, we will discuss the differential diagnosis for abdominal pain, including chronic mesenteric ischaemia (CMI), chronic pancreatitis, diverticulitis, gastric cancer, and acute mesenteric ischaemic embolism.

CMI usually results from atherosclerotic disease of two or more mesenteric vessels, while chronic pancreatitis is characterised by a continuing, chronic, inflammatory process of the pancreas. Diverticulitis is an inflammation of one or more diverticula, while gastric cancer is the third most common cause of cancer-related death in the world. Acute mesenteric ischaemic embolism is characterised by pain that is disproportionate to physical examination findings.

Each condition has its own unique set of symptoms and clinical presentation. By understanding the differential diagnosis for abdominal pain, clinicians can make an accurate diagnosis and provide appropriate treatment for their patients.

Studies have demonstrated that topical steroids are not very effective in the treatment of anal fissures.

Understanding Anal Fissures: Causes, Symptoms, and Treatment

Anal fissures are tears in the lining of the distal anal canal that can be either acute or chronic. Acute fissures last for less than six weeks, while chronic fissures persist for more than six weeks. The most common risk factors for anal fissures include constipation, inflammatory bowel disease, and sexually transmitted infections such as HIV, syphilis, and herpes.

Symptoms of anal fissures include painful, bright red rectal bleeding, with around 90% of fissures occurring on the posterior midline. If fissures are found in other locations, underlying causes such as Crohn’s disease should be considered.

Management of acute anal fissures involves softening stool, dietary advice, bulk-forming laxatives, lubricants, topical anaesthetics, and analgesia. For chronic anal fissures, the same techniques should be continued, and topical glyceryl trinitrate (GTN) is the first-line treatment. If GTN is not effective after eight weeks, surgery (sphincterotomy) or botulinum toxin may be considered, and referral to secondary care is recommended.

In summary, anal fissures can be a painful and uncomfortable condition, but with proper management, they can be effectively treated. It is important to identify and address underlying risk factors to prevent the development of chronic fissures.

Primary biliary cholangitis (PBC) is a chronic liver disease that primarily affects middle-aged women. It is believed to be an autoimmune disorder that causes progressive cholestasis and can lead to end-stage liver disease. Symptoms include fatigue, pruritus, and right upper quadrant discomfort. Laboratory tests typically show elevated levels of alkaline phosphatase, g-glutamyl transpeptidase, and immunoglobulins, as well as the presence of antimitochondrial antibodies. Treatment involves the use of ursodeoxycholic acid to slow disease progression. Autoimmune hepatitis, diffuse systemic sclerosis, primary sclerosing cholangitis, and systemic lupus erythematosus are other potential differential diagnoses.

Gastroenteritis can occur either at home or while traveling, known as travelers’ diarrhea. This condition is characterized by at least three loose to watery stools in 24 hours, accompanied by abdominal cramps, fever, nausea, vomiting, or blood in the stool. The most common cause of travelers’ diarrhea is Escherichia coli. Acute food poisoning is another pattern of illness that results in sudden onset of nausea, vomiting, and diarrhea after ingesting a toxin. Staphylococcus aureus, Bacillus cereus, or Clostridium perfringens are typically responsible for acute food poisoning.

There are several types of infections that can cause gastroenteritis, each with its own typical presentation. Escherichia coli is common among travelers and causes watery stools, abdominal cramps, and nausea. Giardiasis results in prolonged, non-bloody diarrhea, while cholera causes profuse, watery diarrhea and severe dehydration leading to weight loss. Shigella causes bloody diarrhea, vomiting, and abdominal pain, while Staphylococcus aureus results in severe vomiting with a short incubation period. Campylobacter typically starts with a flu-like prodrome and progresses to crampy abdominal pains, fever, and diarrhea, which may be bloody and mimic appendicitis. Bacillus cereus can cause two types of illness, vomiting within six hours, typically due to rice, or diarrheal illness occurring after six hours. Amoebiasis has a gradual onset of bloody diarrhea, abdominal pain, and tenderness that may last for several weeks.

The incubation period for gastroenteritis varies depending on the type of infection. Staphylococcus aureus and Bacillus cereus have an incubation period of 1-6 hours, while Salmonella and Escherichia coli have an incubation period of 12-48 hours. Shigella and Campylobacter have an incubation period of 48-72 hours, while Giardiasis and Amoebiasis have an incubation period of more than seven days.

Patients who have ascites due to liver cirrhosis should receive an aldosterone antagonist, such as spironolactone, as it helps to counteract the secondary hyperaldosteronism that occurs in cirrhosis. This condition attempts to increase intravascular volume, which is lost into the abdomen as ascites. Amiloride is not effective in treating ascites as it does not lead to significant diuresis and has no effect on the aldosterone pathway. Eplerenone is an alternative to spironolactone for patients who cannot tolerate its adverse effects. Furosemide is useful in treating ascites but should be used in conjunction with spironolactone due to the additional benefits of aldosterone blocking. Bendroflumethiazide is not useful in managing or preventing fluid overload conditions such as ascites.

Understanding Ascites: Causes and Management

Ascites is a medical condition characterized by the accumulation of abnormal fluid in the abdomen. The causes of ascites can be classified into two groups based on the serum-ascites albumin gradient (SAAG) level. A SAAG level greater than 11g/L indicates portal hypertension, which is commonly caused by liver disorders such as cirrhosis, alcoholic liver disease, and liver metastases. On the other hand, a SAAG level less than 11g/L is caused by hypoalbuminaemia, malignancy, infections, and other factors such as bowel obstruction and biliary ascites.

The management of ascites involves reducing dietary sodium and fluid restriction, especially if the sodium level is less than 125 mmol/L. Aldosterone antagonists like spironolactone and loop diuretics are often prescribed to patients. In some cases, drainage through therapeutic abdominal paracentesis is necessary. Large-volume paracentesis requires albumin cover to reduce the risk of paracentesis-induced circulatory dysfunction and mortality. Prophylactic antibiotics are also recommended to prevent spontaneous bacterial peritonitis. In severe cases, a transjugular intrahepatic portosystemic shunt (TIPS) may be considered.

Understanding the causes and management of ascites is crucial in providing appropriate medical care to patients. Proper diagnosis and treatment can help alleviate symptoms and improve the patient’s quality of life.

Patients with Parkinsonism should not take metoclopramide due to its dopamine antagonist properties, which can exacerbate their symptoms.

Metoclopramide is a medication that is commonly used to manage nausea. It works by blocking D2 receptors in the chemoreceptor trigger zone, which helps to alleviate feelings of sickness. In addition to its antiemetic properties, metoclopramide also has other uses, such as treating gastro-oesophageal reflux disease and gastroparesis caused by diabetic neuropathy. It is often combined with analgesics to treat migraines, which can cause gastroparesis and slow the absorption of pain medication.

However, metoclopramide can have some adverse effects, such as extrapyramidal effects, acute dystonia, diarrhoea, hyperprolactinaemia, tardive dyskinesia, and parkinsonism. These side effects are particularly problematic in children and young adults. It is important to note that metoclopramide should not be used in cases of bowel obstruction, but it may be helpful in cases of paralytic ileus.

Although metoclopramide primarily works as a D2 receptor antagonist, its mechanism of action is quite complex. It also acts as a mixed 5-HT3 receptor antagonist and 5-HT4 receptor agonist. The antiemetic effects of metoclopramide are due to its D2 receptor antagonist activity in the chemoreceptor trigger zone, while its gastroprokinetic effects are mediated by both D2 receptor antagonist and 5-HT4 receptor agonist activity. At higher doses, the 5-HT3 receptor antagonist activity also comes into play.

To prevent spontaneous bacterial peritonitis, it is recommended to administer oral ciprofloxacin or norfloxacin as prophylaxis to patients with ascites and protein concentration of 15 g/L or less.

Understanding Spontaneous Bacterial Peritonitis

Spontaneous bacterial peritonitis (SBP) is a type of peritonitis that typically affects individuals with ascites caused by liver cirrhosis. The condition is characterized by symptoms such as abdominal pain, fever, and ascites. Diagnosis is usually made through paracentesis, which involves analyzing the ascitic fluid for a neutrophil count of over 250 cells/ul. The most common organism found on ascitic fluid culture is E. coli.

Management of SBP typically involves the administration of intravenous cefotaxime. Antibiotic prophylaxis is also recommended for patients with ascites who have previously experienced an episode of SBP or have a fluid protein level of less than 15 g/l and a Child-Pugh score of at least 9 or hepatorenal syndrome. NICE recommends prophylactic oral ciprofloxacin or norfloxacin until the ascites has resolved.

Alcoholic liver disease is a significant predictor of poor prognosis in SBP. Understanding the symptoms, diagnosis, and management of SBP is crucial for healthcare professionals to provide appropriate care and improve patient outcomes.

Please limit your alcohol consumption to a maximum of 21 units per week, with no more than 3 units in a single day.

Alcohol consumption guidelines were revised in 2016 by the Chief Medical Officer, based on recommendations from an expert group report. The most significant change was a reduction in the recommended maximum number of units of alcohol for men from 21 to 14, aligning with the guidelines for women. The government now advises that both men and women should not exceed 14 units of alcohol per week, and if they do, it is best to spread it evenly over three or more days. Pregnant women are advised not to drink alcohol at all, as it can cause long-term harm to the baby. One unit of alcohol is equivalent to 10 mL of pure ethanol, and the strength of a drink is determined by its alcohol by volume (ABV). Examples of one unit of alcohol include a 25ml single measure of spirits with an ABV of 40%, a third of a pint of beer with an ABV of 5-6%, and half a 175ml standard glass of red wine with an ABV of 12%. To calculate the number of units in a drink, multiply the number of millilitres by the ABV and divide by 1,000.

Managing Crohn’s Disease: Guidelines and Treatment Options

Crohn’s disease is a type of inflammatory bowel disease that can affect any part of the digestive tract. To manage this condition, the National Institute for Health and Care Excellence (NICE) has published guidelines that provide recommendations for inducing and maintaining remission, as well as treating complications. One of the most important steps in managing Crohn’s disease is to advise patients to quit smoking, as this can worsen the condition. Additionally, some medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and the combined oral contraceptive pill, may increase the risk of relapse, although the evidence is not conclusive.

To induce remission, glucocorticoids are often used, either orally, topically, or intravenously. Budesonide is an alternative for some patients. Enteral feeding with an elemental diet may also be used, especially in young children or when there are concerns about the side effects of steroids. Second-line treatments for inducing remission include 5-ASA drugs like mesalazine, as well as azathioprine or mercaptopurine, which may be used in combination with other medications. Methotrexate is another option. Infliximab is useful for refractory disease and fistulating Crohn’s, and patients may continue on azathioprine or methotrexate.

To maintain remission, stopping smoking is a priority, and azathioprine or mercaptopurine is used first-line. TPMT activity should be assessed before starting these medications. Methotrexate is used second-line. Surgery may be necessary for around 80% of patients with Crohn’s disease, depending on the location and severity of the disease. Complications of Crohn’s disease include small bowel cancer, colorectal cancer, and osteoporosis. Perianal fistulae and abscesses require specific treatments, such as oral metronidazole, anti-TNF agents like infliximab, or a draining seton. By following these guidelines and treatment options, patients with Crohn’s disease can better manage their condition and improve their quality of life.

Treatment Options for Helicobacter pylori Infection

Helicobacter pylori is a common bacterial infection that can cause dyspepsia and gastro-oesophageal reflux disease (GORD). There are several treatment options available for patients who test positive for H. pylori.

One option is a 7-day course of a proton pump inhibitor (PPI), amoxicillin, and either clarithromycin or metronidazole. This should be followed by a PPI for 4-8 weeks. Patients who are allergic to penicillin and have had previous exposure to clarithromycin should be offered a 7-day course of a PPI, bismuth, metronidazole, and tetracycline.

Long-term PPI and dietary advice alone will not eradicate H. pylori. If symptoms return after initial care strategies for dyspepsia, step down PPI therapy to the lowest dose needed to control symptoms. Patients with GORD should be offered full-dose PPI.

It is important to consult the British National Formulary (BNF) for appropriate doses of each drug, as they may vary. Sucralfate has no role in the eradication of H. pylori.

The patient’s symptoms of dull, central abdominal pain that worsens after meals and radiates to the back, along with a history of regular alcohol consumption, suggest a diagnosis of chronic pancreatitis. Imaging studies, such as an abdominal X-ray or CT scan, may reveal pancreatic calcifications, which are a common finding in chronic pancreatitis. If imaging is inconclusive, a faecal elastase test may be used to assess pancreatic exocrine function. The presence of the football sign, air under the diaphragm, dilated loops of small bowel, or the Rigler sign on an abdominal X-ray would suggest other conditions such as gastrointestinal perforation or bowel obstruction, which do not fit the patient’s presentation.

If a patient experiences new-onset dysphagia, urgent endoscopy is necessary regardless of age or other symptoms. In the case of progressive dysphagia, it is crucial to rule out oesophageal or stomach cancer with a two week wait referral for gastroscopy. Gastroparesis, a delay in gastric emptying associated with diabetes, can be treated with metoclopramide. Plummer-vinson syndrome, which is characterized by iron deficiency anaemia and oesophageal webs, can also cause dysphagia along with glossitis and stomatitis. Gaviscon is not a suitable treatment for dysphagia as it only helps with dyspepsia. While a stroke can cause difficulties in initiating swallowing, it is typically sudden onset rather than progressive.

Understanding Dysphagia and its Causes

Dysphagia, or difficulty in swallowing, can be caused by various conditions affecting the esophagus, such as oesophageal cancer, oesophagitis, oesophageal candidiasis, achalasia, pharyngeal pouch, systemic sclerosis, and myasthenia gravis. Each condition has its own characteristic features, which can help in identifying the underlying cause of dysphagia. For instance, dysphagia associated with weight loss, anorexia, or vomiting during eating may indicate oesophageal cancer, while dysphagia of both liquids and solids from the start may suggest achalasia.

To determine the cause of dysphagia, patients usually undergo an upper GI endoscopy, which allows doctors to examine the esophagus and detect any abnormalities. Fluoroscopic swallowing studies may also be done to evaluate motility disorders. Additionally, a full blood count and ambulatory oesophageal pH and manometry studies may be required for certain conditions.

It’s important to note that new-onset dysphagia is a red flag symptom that requires urgent endoscopy, regardless of age or other symptoms. Therefore, understanding the different causes of dysphagia and their characteristic features can aid in prompt diagnosis and treatment.

In order to diagnose coeliac disease, endoscopic intestinal biopsy is considered the most reliable method and should be performed on all patients who show signs of the condition based on serology. A young patient with non-specific symptoms that suggest coeliac disease has been found to have mild anaemia and elevated coeliac serology. While these results are suggestive, they are not conclusive, and putting the patient on a gluten-free diet without further testing could be detrimental to their quality of life. Therefore, an intestinal biopsy without dietary modification is necessary to confirm the diagnosis. If the patient excludes gluten prior to the biopsy, the results may not be significant, so it is important to continue or reintroduce gluten for at least 6 weeks before the procedure. The expected results of a biopsy for coeliac disease include villous atrophy, crypt hyperplasia, increased intraepithelial lymphocytes, and lymphocyte infiltration in the lamina propria. It is incorrect to assume that the patient does not require further testing, as the antibody results are not conclusive. Repeating antibody tests without dietary modification or advising the patient to exclude gluten and repeat the tests are also unnecessary. However, repeating antibody tests after a confirmed diagnosis may be useful in assessing patient adherence to a gluten-free diet. The patient should be referred to a gastroenterologist for an intestinal biopsy to confirm the diagnosis.

Investigating Coeliac Disease

Coeliac disease is a condition caused by sensitivity to gluten, which can lead to villous atrophy and malabsorption. It is often associated with other conditions such as dermatitis herpetiformis and autoimmune disorders. Diagnosis of coeliac disease is made through a combination of serology and endoscopic intestinal biopsy. The gold standard for diagnosis is the biopsy, which should be performed in all patients with suspected coeliac disease to confirm or exclude the diagnosis. The biopsy traditionally takes place in the duodenum, but jejunal biopsies are also sometimes performed. Findings supportive of coeliac disease include villous atrophy, crypt hyperplasia, an increase in intraepithelial lymphocytes, and lamina propria infiltration with lymphocytes. Serology tests for coeliac disease include tissue transglutaminase antibodies and endomyseal antibodies, while anti-gliadin antibodies are not recommended. Patients who are already on a gluten-free diet should reintroduce gluten for at least six weeks prior to testing. Rectal gluten challenge is not widely used. A gluten-free diet can reverse villous atrophy and immunology in patients with coeliac disease.

Lifestyle Advice for Patients with Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a chronic inflammatory process that can affect any part of the gastrointestinal tract. Patients with IBD may experience symptoms such as diarrhoea, abdominal pain, and bleeding. Here are some lifestyle advice for patients with IBD:

Stop smoking: Research suggests that smoking can make Crohn’s disease worse. Smokers with Crohn’s disease have more severe symptoms and complications, require more medication, and are more likely to need surgery.

Eat a balanced diet: Patients with IBD may need to be careful about the amount and type of fibre in their diet. During flare-ups, it may be helpful to reduce the amount of insoluble fibre consumed, but, once the flare-up is over, it is important to increase fibre intake again.

Avoid alcohol: Although there is no evidence that alcohol consumption worsens IBD symptoms, alcohol can affect the lining of the gastrointestinal tract and interact with certain medications.

Quit smoking: Although smoking may delay or even prevent ulcerative colitis, the health risks of smoking outweigh any benefits seen in UC, and strongly discourage smoking in everyone, whether or not they have IBD.

Consider probiotics: The role of probiotics in IBD is not fully understood, but their use can be discussed with a General Practitioner or dietitian. More research is needed on their general effectiveness.

It is possible that this individual has developed toxic megacolon, which is characterized by a transverse colon diameter exceeding 6 cm and accompanying symptoms of systemic distress. Treatment for toxic megacolon typically involves intensive medical intervention for a period of 24-72 hours. If there is no improvement in the patient’s condition during this time, a colectomy may be necessary.

Understanding Ulcerative Colitis Flares

Ulcerative colitis is a chronic inflammatory bowel disease that can cause flares or periods of worsening symptoms. While most flares occur without a clear trigger, there are several factors that are often associated with them. These include stress, certain medications such as NSAIDs and antibiotics, and even quitting smoking.

Flares of ulcerative colitis can be classified as mild, moderate, or severe based on the frequency and severity of symptoms. Mild flares may involve fewer than four stools a day with or without blood, while moderate flares may include four to six stools a day with minimal systemic disturbance. Severe flares, on the other hand, may involve more than six stools a day containing blood, as well as evidence of systemic disturbance such as fever, tachycardia, abdominal tenderness, distension, reduced bowel sounds, anemia, and hypoalbuminemia.

Patients with evidence of severe disease should be admitted to the hospital for close monitoring and treatment. Understanding the triggers and symptoms of ulcerative colitis flares can help patients manage their condition and seek appropriate medical care when necessary.

Chronic haemolysis and gallstone formation are present in this patient with hereditary spherocytosis. It is crucial to consider splenic rupture as a potential differential diagnosis in a patient with hereditary spherocytosis who is unwell.

Understanding Hereditary Spherocytosis

Hereditary spherocytosis is the most common hereditary haemolytic anaemia in people of northern European descent. It is an autosomal dominant defect of the red blood cell cytoskeleton, which replaces the normal biconcave disc shape with a sphere-shaped red blood cell. This condition reduces the red blood cell survival as they are destroyed by the spleen. Patients with hereditary spherocytosis may present with failure to thrive, jaundice, gallstones, splenomegaly, and aplastic crisis precipitated by parvovirus infection. The degree of haemolysis is variable, and the mean corpuscular haemoglobin concentration (MCHC) is elevated.

The diagnosis of hereditary spherocytosis is based on a family history of the condition, typical clinical features, and laboratory investigations such as spherocytes, raised MCHC, and an increase in reticulocytes. The osmotic fragility test was previously the recommended investigation of choice, but it is now deemed unreliable and is no longer recommended. If the diagnosis is equivocal, the EMA binding test and the cryohaemolysis test are recommended. For atypical presentations, electrophoresis analysis of erythrocyte membranes is the method of choice.

The management of hereditary spherocytosis involves supportive treatment during acute haemolytic crisis, including transfusion if necessary. Longer-term treatment includes folate replacement and splenectomy. It is important to note that hereditary spherocytosis differs from G6PD deficiency, which is an X-linked recessive condition that affects males of African and Mediterranean descent. The diagnostic test for G6PD deficiency involves measuring enzyme activity, while the EMA binding test is used for hereditary spherocytosis.

The presence of fever, jaundice, and pain in the right upper quadrant indicates Charcot’s cholangitis triad, which is commonly associated with ascending cholangitis. This combination of symptoms is not typically seen in cases of acute cholecystitis.

Understanding Ascending Cholangitis

Ascending cholangitis is a bacterial infection that affects the biliary tree, with E. coli being the most common culprit. This condition is often associated with gallstones, which can predispose individuals to the infection. Patients with ascending cholangitis may present with Charcot’s triad, which includes fever, right upper quadrant pain, and jaundice. However, this triad is only present in 20-50% of cases. Other common symptoms include hypotension and confusion. In severe cases, Reynolds’ pentad may be observed, which includes the additional symptoms of hypotension and confusion.

To diagnose ascending cholangitis, ultrasound is typically used as a first-line investigation to look for bile duct dilation and stones. Raised inflammatory markers may also be observed. Treatment involves intravenous antibiotics and endoscopic retrograde cholangiopancreatography (ERCP) after 24-48 hours to relieve any obstruction.

Overall, ascending cholangitis is a serious condition that requires prompt diagnosis and treatment. Understanding the symptoms and risk factors associated with this condition can help individuals seek medical attention early and improve their chances of a successful recovery.